Literature DB >> 11096609

Acute Viral Hepatitis.

.   

Abstract

The mainstay of treatment for acute viral hepatitis is supportive care, as most cases are self-limited. General measures in all types of acute viral hepatitis include bedrest if the patient is very symptomatic, a high-calorie diet, avoidance of hepatotoxic medications, and abstinence from alcohol with the anticipation that most patients will recover uneventfully. In severe cases, hospitalization may be necessary for intravenous rehydration if the patient is unable to maintain adequate oral intake due to nausea and vomiting or if there is any alteration of mental status to suggest evolving fulminant hepatic failure. Acute hepatitis A is a self-limited disease, but can be fulminant. Lamivudine at a dosage of 100 mg/d orally may be beneficial in acute hepatitis B. Interferon-alpha therapy in acute hepatitis C may decrease the risk of developing chronic hepatitis C. Fulminant liver failure due to acute viral hepatitis is uncommon, but orthotopic liver transplantation occasionally may be life saving.

Entities:  

Year:  2000        PMID: 11096609     DOI: 10.1007/s11938-000-0037-4

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  5 in total

1.  Successful use of lamivudine for severe acute hepatitis B virus infection in a cardiac transplant recipient.

Authors:  G Dulai; L Higa; J Kobashigawa; P Martin
Journal:  Transplantation       Date:  1999-05-15       Impact factor: 4.939

2.  Interferon as treatment for acute hepatitis C. A meta-analysis.

Authors:  C Cammà; P Almasio; A Craxì
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

3.  High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study.

Authors:  W Vogel; I Graziadei; F Umlauft; C Datz; F Hackl; S Allinger; K Grünewald; J Patsch
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 4.  Serologic diagnosis of viral hepatitis.

Authors:  M H Sjogren
Journal:  Med Clin North Am       Date:  1996-09       Impact factor: 5.456

5.  Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.

Authors:  J S Markowitz; P Martin; A J Conrad; J F Markmann; P Seu; H Yersiz; J A Goss; P Schmidt; A Pakrasi; L Artinian; N G Murray; D K Imagawa; C Holt; L I Goldstein; R Stribling; R W Busuttil
Journal:  Hepatology       Date:  1998-08       Impact factor: 17.425

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.